Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enforcing A Belated Chemistry Lesson – The Nitrosamines In Sartans Saga

Executive Summary

How authorities plan to root out the carcinogenic impurities and what it means for other classes of medicines.

You may also be interested in...



US FDA Sets Out Nitrosamines Guidance

Agency guidance establishes process for ridding unsafe levels of the probable carcinogens from the pharmaceutical supply chain.

US FDA Advises Manufacturers To Test For Nitrosamines In All APIs, Drug Products

Guidance is FDA's latest action in response to findings that over time in storage, especially at higher temperatures, levels of the probable carcinogen NDMAincreases in some ingredients, including ranitidine available in OTC heartburn remedies.

US FDA Expectations For Removing Nitrosamines From All APIs, Drug Products

Agency guidance establishes process for ridding unsafe levels of the probable carcinogens from the pharmaceutical supply chain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel